Literature DB >> 31898759

Differences in cognitive profiles between Lewy body and Parkinson's disease dementia.

Alice Martini1, Luca Weis2, Roberta Schifano2, Francesca Pistonesi3, Eleonora Fiorenzato2, Angelo Antonini3, Roberta Biundo4.   

Abstract

Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) not only differ for the time of onset of cognitive deficits but also present variability in affected functions which are relevant in understanding underlying pathology. Cognitive performance of two global cognitive screening scales, the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), as well as of a neuropsychological test battery, was evaluated in 18 DLB and 21 PDD patients. Feasibility for each cognitive test was investigated. Both MMSE and MoCA are feasible assessments in PDD and DLB patients. MoCA was more sensitive in discriminating groups as higher number of DLB patients showed pathological performances on the Digit Span Forward subitem (p = 0.049). The Stroop test in PDD and the Trail Making Tests-A and B, and the Benton's judgment of line orientation tests in both groups were considered not feasible. Among feasible cognitive tests in at least one group, Rey-Osterrieth complex figure test copy (p = 0.013) and semantic fluency (p = 0.038) are sensitive in discriminating DLB from PDD cognitive profile. Trail Making Tests-A and B, the Benton's judgment of line orientation and the Stroop tests are not feasible for assessing patients with frank dementia. Longitudinal studies should not include those tasks to reduce the risk of missing data once disease progresses and dementia develops. DLB patients present more severe and widespread cognitive dysfunction than PDD, particularly in attentive, visuospatial, and language domains.

Entities:  

Keywords:  Cognition; Dementia with Lewy bodies; Feasibility; Mini-Mental State Examination (MMSE); Montreal Cognitive Assessment (MoCA); Parkinson’s dementia

Mesh:

Year:  2020        PMID: 31898759     DOI: 10.1007/s00702-019-02129-2

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  21 in total

Review 1.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Authors:  Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre
Journal:  Mov Disord       Date:  2012-01-24       Impact factor: 10.338

2.  Striatal beta-amyloid deposition in Parkinson disease with dementia.

Authors:  Michail E Kalaitzakis; Manuel B Graeber; Stephen M Gentleman; Ronald K B Pearce
Journal:  J Neuropathol Exp Neurol       Date:  2008-02       Impact factor: 3.685

3.  Impaired Cognition and the Risk of Parkinson Disease: Trouble in Mind.

Authors:  Ethan G Brown; Caroline M Tanner
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

4.  MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study.

Authors:  Roberta Biundo; L Weis; S Bostantjopoulou; E Stefanova; C Falup-Pecurariu; M G Kramberger; G J Geurtsen; A Antonini; D Weintraub; D Aarsland
Journal:  J Neural Transm (Vienna)       Date:  2016-02-06       Impact factor: 3.575

5.  Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia.

Authors:  Hiroshige Fujishiro; Eizo Iseki; Shinji Higashi; Koji Kasanuki; Norio Murayama; Takashi Togo; Omi Katsuse; Hirotake Uchikado; Naoya Aoki; Kenji Kosaka; Heii Arai; Kiyoshi Sato
Journal:  Neurosci Lett       Date:  2010-09-17       Impact factor: 3.046

6.  Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.

Authors:  Eleonora Fiorenzato; Luca Weis; Cristian Falup-Pecurariu; Stefania Diaconu; Chiara Siri; Elisa Reali; Gianni Pezzoli; Patrizia Bisiacchi; Angelo Antonini; Roberta Biundo
Journal:  J Neural Transm (Vienna)       Date:  2016-06-22       Impact factor: 3.575

7.  Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia.

Authors:  Roberta Biundo; Luca Weis; Silvia Facchini; Patrizia Formento-Dojot; Annamaria Vallelunga; Manuela Pilleri; Angelo Antonini
Journal:  Parkinsonism Relat Disord       Date:  2014-01-22       Impact factor: 4.891

8.  Distribution and Load of Amyloid-β Pathology in Parkinson Disease and Dementia with Lewy Bodies.

Authors:  Dagmar H Hepp; Dana L E Vergoossen; Evelien Huisman; Afina W Lemstra; Henk W Berendse; Annemieke J Rozemuller; Elisabeth M J Foncke; Wilma D J van de Berg
Journal:  J Neuropathol Exp Neurol       Date:  2016-08-11       Impact factor: 3.685

9.  Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

Authors:  Yaroslau Compta; Laura Parkkinen; Sean S O'Sullivan; Jana Vandrovcova; Janice L Holton; Catherine Collins; Tammaryn Lashley; Constantinos Kallis; David R Williams; Rohan de Silva; Andrew J Lees; Tamas Revesz
Journal:  Brain       Date:  2011-05       Impact factor: 13.501

Review 10.  Clinical diagnostic criteria for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Richard Brown; David J Burn; Charles Duyckaerts; Yoshikino Mizuno; Gerald Anthony Broe; Jeffrey Cummings; Dennis W Dickson; Serge Gauthier; Jennifer Goldman; Christopher Goetz; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Ian McKeith; Warren Olanow; Werner Poewe; Niall Quinn; Christina Sampaio; Eduardo Tolosa; Bruno Dubois
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

View more
  1 in total

1.  An Adaptive Measure of Visuospatial Impairment in Dementia with Lewy Bodies.

Authors:  Joseph R Phillips; Elie Matar; Kaylena A Ehgoetz Martens; Ahmed A Moustafa; Glenda M Halliday; Simon J G Lewis
Journal:  Mov Disord Clin Pract       Date:  2022-06-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.